Variantyx

Company Overview

Snapshot

Founded in May 2014 by Haim Neerman, Noam Shomron, and Tomer Jackman, Variantyx operates with 201–500 employees. The company has raised a total of $131.5M across 10 funding rounds from 12 investors. In April 2024, Variantyx secured an additional investment, enabling rapid expansion of its commercial footprint.

Business overview

Variantyx is an award-winning, technology-driven molecular diagnostics lab that provides innovative solutions across genetic disorders, reproductive health, and precision oncology markets. The company leverages its proprietary whole genome analysis platform to deliver diagnostic capabilities, enhance personalized treatment recommendations, and reduce time to diagnosis and healthcare costs. Variantyx offers a range of test options, from targeted to comprehensive analyses, all performed on a whole genome platform, allowing for seamless reflexing to more extensive analysis without requiring additional samples or sequencing. The company operates in the Digital Medical Diagnostics sector, utilizing Artificial Intelligence and Software platforms, and serves healthcare providers, laboratories, and pharmaceutical companies.

Strategic signal

In September 2024, Variantyx launched Genomic Unity® 2.0, introducing the first combined short- and long-read whole genome sequencing test to the market. This development signifies a major advancement in genomic diagnostics, potentially improving the accuracy and comprehensiveness of genetic testing. For investors, this indicates Variantyx's continued innovation and leadership in the precision medicine space, positioning the company for enhanced market penetration and competitive advantage.

Company Intelligence Q&A

What significant product did Variantyx launch recently?

In September 2024, Variantyx launched Genomic Unity® 2.0, which is the first combined short- and long-read whole genome sequencing test available in the market.

Which investors participated in Variantyx's April 2024 funding round?

In April 2024, Variantyx received investment from Peregrine Ventures and Robert Bosch Venture Capital.

What was a key strategic move for Variantyx in October 2023?

In October 2023, Variantyx announced an additional investment, which was intended to enable the rapid expansion of its commercial footprint. Investors included Peregrine Ventures and 20/20 HealthCare Partners.

What was a notable expansion of Variantyx's offerings in late 2023?

In November 2023, Variantyx expanded its reproductive health offerings by launching a direct replacement for Chromosomal Microarray Analysis.